Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73063 | 0.97 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Bromide SCHEMBL27764653 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrogen Sulfide SCHEMBL27894390 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrogen Sulfide SCHEMBL28066375 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28079189 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28727492 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28079333 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28079327 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL3674757 | 0.95 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL27886095 | 0.93 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569581-B2 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | claimed |
| US-20060270667-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-30 | — | — | US | claimed |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-08 | — | — | US | claimed |
| US-6706726-B2 | QUATERNIZED DIARYLACETOXY-SUBSTITUTED NORTROPANE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-16 | — | — | US | claimed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-20050154555-A1 | Measuring device for rapid non-destructive measurement of the contents of capsules | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20040087617-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-6706726-B2 | QUATERNIZED DIARYLACETOXY-SUBSTITUTED NORTROPANE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-16 | — | — | US | disclosed |
| US-20040010003-A1 | 9,9-dimethyl-3-oxa-9-azoniumtricyclo(3.3.1.0(2,4))nonanyl 2,2-diphenylpropionate quaternary salt | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | US | disclosed |
| US-20040002502-A1 | Medicament combinations comprising heterocyclic compounds and a novel anticholinergic | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-01 | — | — | US | disclosed |
| US-20030223937-A1 | Medicaments comprising steroids and a novel anticholinergic | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20020115680-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270667-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | ADRB3, CHRM3, ADRB2 | HDAC3 2167/4885HDAC4 1345/4885HDAC1 2385/4885 |
| US-20040002502-A1 | Medicament combinations comprising heterocyclic compounds and a novel anticholinergic | CHRM3, ACHE, CHRM2 | HDAC3 560/4885HDAC4 981/4885HDAC1 1278/4885 |
| US-20020115680-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM2, CHRM1, CHRM5 | HDAC3 2467/4885HDAC4 1403/4885HDAC1 1937/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | HDAC3 908/4885HDAC4 2542/4885HDAC1 1612/4885 |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM1, CHRM2, CHRM3 | HDAC3 2183/4885HDAC4 2193/4885HDAC1 1658/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | HDAC3 3780/4885HDAC4 3106/4885HDAC1 4778/4885 |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | ADRA2C, ADRA1D, ADRB1 | HDAC3 2022/4885HDAC4 2518/4885HDAC1 1927/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC3 908/4885HDAC4 2542/4885HDAC1 1612/4885 |
| US-20040087617-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM1, CHRM2, CHRM5 | HDAC3 2463/4885HDAC4 1778/4885HDAC1 2166/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | HDAC3 908/4885HDAC4 2542/4885HDAC1 1612/4885 |
| US-20030223937-A1 | Medicaments comprising steroids and a novel anticholinergic | CHRM3, CHRM2, CHRNB1 | HDAC3 2339/4885HDAC4 1356/4885HDAC1 1263/4885 |
| US-20040010003-A1 | 9,9-dimethyl-3-oxa-9-azoniumtricyclo(3.3.1.0(2,4))nonanyl 2,2-diphenylpropionate quaternary salt | ADRB1, ADRB3, ADRB2 | HDAC3 2796/4885HDAC4 3450/4885HDAC1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.